Advanced Search

 

Study ID Status Title Patient Level Data
25000/590 Completed Ways of use in ENT practice of a new Augmentin formulation 1g/125mg (1 intake = 2 tablets 500mg/62.5mg) in treatment of acute sinusitis in adults.
25000/591 Completed A double-blind, placebo-controlled, randomised, phase III clinical trial to compare the efficacy of oral Augmentin SR 2000/125 to placebo given as a single dose as prophylaxis or twice daily over 5 days as treatment to reduce the infective and inflammatory complications after undergoing maxillofacial surgery for third mandibular molar removal.
25000/592 Completed An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral AUGMENTIN SR 2000/125mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults. Study Listed on ClinicalStudyDataRequest.com
25000/593 Completed A randomized open label, 4 period, crossover study to determine the bioequivalence of scored tablets of pharmacokinetically enhanced AUGMENTIN (administered as two tablets which have been broken in half) to unscored whole tablets of pharmacokinetically enhanced AUGMENTIN in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
25000/600 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia. Study Listed on ClinicalStudyDataRequest.com
25000/601 Completed A Study to Determine the Bioequivalence of Reformulated Augmentin Suspension (improved stability) to Standard Marketed Suspension. Study Listed on ClinicalStudyDataRequest.com
25000/610 Completed A double blind study to compare the subject preference for Augmentin suspension formulations with alternative flavours in healthy paediatric subjects.
25000/611 Completed A Randomized, Investigator-Blind, Multicenter Study to Assess the Efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 Days Versus Oral Zithromax Once Daily for 5 Days in the Treatment of Acute Otitis Media in Infants and Children. Study Listed on ClinicalStudyDataRequest.com
25000/620 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days in the Treatment of Adults with Community Acquired Pneumonia of Suspected Pneumococcal Origin. Study Listed on ClinicalStudyDataRequest.com
25000/627 Completed A randomized, double-blind, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus a 7-day regimen in the treatment of acute exacerbation of chronic bronchitis Study Listed on ClinicalStudyDataRequest.com
25000/630 Completed A randomised, double-blind, double-dummy, multicentre, parallel group study to assess the efficacy and safety of oral Augmentin SR 2000/125mg twice daily for 5 days versus oral Augmentin 875/125mg twice daily for 7 days in the treatment of adults with acute exacerbations of chronic bronchitis. Study Listed on ClinicalStudyDataRequest.com
25000/643 Completed A bioequivalence study to compare the currently marketed formulation of augmentin with the ES 600 Strawberry Cream Suspension (4A) Study Listed on ClinicalStudyDataRequest.com
25000/654 Completed A Phase III open-label, non-comparative study of BRL25000 ES-600 in paediatric patients with otitis media
25000/665 Completed An open-label, randomized, period balanced, replicate, four-period crossover bioequivalence study comparing AUGMENTIN ES-600 strawberry cream formulation to the marketed suspension. Study Listed on ClinicalStudyDataRequest.com
25000/668 Completed An uncontrolled, phase I study to determine ex vivo the serum bactericidal activity against Streptococcus pneumoniae with decreased susceptibility to amoxicillin in the presence of factors of non-specific immunity with and without specific antibodies, the urine bactericidal activity against Escheric
257049/005 Completed Phase IIb controlled randomised double-blind study to evaluate the efficacy, safety and immunogenicity of SmithKline Beecham Biologicals’ candidate RTS,S malaria vaccine in semi-immune adult males in The Gambia.
257049/015 Completed Staggered study to evaluate safety and immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to a 0,1,3-month schedule in semi-immune children aged 6 to 11 years in Gambia, a malaria endemic region Study Listed on ClinicalStudyDataRequest.com
257049/020 Completed Staggered study to evaluate safety & immunogenicity of GSK Biologicals RTS,S/AS02 candidate malaria vaccine, administered intramuscularly according to 0,1,3-month schedule in toddlers and children aged 1 through 5 years in Gambia, a malaria endemic region
257049/025 Completed A phase I, double-blind, randomized, controlled, study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate vaccine, administered intramuscularly according to a 0, 1, 2-month vaccination schedule in children aged 1 through 4 Study Listed on ClinicalStudyDataRequest.com
257049/026 Completed A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique. Study Listed on ClinicalStudyDataRequest.com
257049/027 Completed Double-blind, randomized phase I/IIa human challenge study, to evaluate the safety, reactogenicity, immunogenicity, and preliminary efficacy after primary sporozoite challenge and rechallenge, of GSK Biologicals’ candidate malaria vaccines containing the antigen RTS,S adjuvanted with either AS02A or AS01B and administered intramuscularly at months 0, 1, 2 in healthy malaria-naive volunteers aged 18 - 45 years Study Listed on ClinicalStudyDataRequest.com
257049/034 Completed A bridging study to evaluate the safety and immunogenicity of GSK Biologicals’ candidate vaccines RTS,S/AS02D (0.5 mL dose) and RTS,S/AS02A (0.25 mL dose) administered according to a 0, 1, 2 month vaccination schedule in children aged 3 to 5 years living in a malaria-endemic region of Mozambique.
26090/007 Completed A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression Study Listed on ClinicalStudyDataRequest.com
263855/001 Completed Single-blind, randomised clinical study to assess and compare the immunogenicity and reactogenicity of the SB Biologicals dTpa, Pa and pa vaccines, and 2 commercial Td vaccines when administered as a booster dose to healthy adolescents, previously vaccinated with the DTP whole cell vaccine (DTPw)
263855/002 Completed Single-blind, clinical study of the immunogenicity and reactogenicity of SB Biologicals’ dTpa, pa vaccines and a Td vaccine, given as a booster dose to healthy adults, from the age of 18 years onwards

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.